- Home
- PAVS vs IMAB Comparison
PAVS vs IMAB Comparison
Compare PAVS & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAVS
- IMAB
- Stock Information
- Founded
- PAVS 2004
- IMAB 2014
- Country
- PAVS United States
- IMAB United States
- Employees
- PAVS N/A
- IMAB N/A
- Industry
- PAVS Medicinal Chemicals and Botanical Products
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- PAVS Health Care
- IMAB Health Care
- Exchange
- PAVS Nasdaq
- IMAB Nasdaq
- Market Cap
- PAVS 89.6M
- IMAB 73.9M
- IPO Year
- PAVS 2019
- IMAB 2020
- Fundamental
- Price
- PAVS $0.86
- IMAB $2.50
- Analyst Decision
- PAVS
- IMAB Strong Buy
- Analyst Count
- PAVS 0
- IMAB 2
- Target Price
- PAVS N/A
- IMAB $5.50
- AVG Volume (30 Days)
- PAVS 5.8K
- IMAB 1.0M
- Earning Date
- PAVS 07-31-2025
- IMAB 05-15-2025
- Dividend Yield
- PAVS N/A
- IMAB N/A
- EPS Growth
- PAVS N/A
- IMAB N/A
- EPS
- PAVS N/A
- IMAB N/A
- Revenue
- PAVS $6,613,273.00
- IMAB N/A
- Revenue This Year
- PAVS N/A
- IMAB N/A
- Revenue Next Year
- PAVS N/A
- IMAB N/A
- P/E Ratio
- PAVS N/A
- IMAB N/A
- Revenue Growth
- PAVS 2.50
- IMAB N/A
- 52 Week Low
- PAVS $0.32
- IMAB $0.60
- 52 Week High
- PAVS $1.50
- IMAB $3.08
- Technical
- Relative Strength Index (RSI)
- PAVS 37.23
- IMAB 67.42
- Support Level
- PAVS $0.85
- IMAB $2.29
- Resistance Level
- PAVS $0.93
- IMAB $2.69
- Average True Range (ATR)
- PAVS 0.05
- IMAB 0.35
- MACD
- PAVS 0.00
- IMAB 0.00
- Stochastic Oscillator
- PAVS 26.32
- IMAB 64.53
About PAVS Paranovus Entertainment Technology Ltd.
Paranovus Entertainment Technology Ltd through its subsidiary, is engaged in the AI-powered entertainment industry, aiming to provide users with AI-driven games and applications to deliver immersive and engaging entertainment experiences. It is planning to launch SimTwin application which will allow users to interact with digital versions of people and capture life moments. The company also has a software development agreement with Blueline Studios Inc which is developing 10,000 Lives, a mobile game where players pursue various careers and life goals using a board game mechanic.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).